XML 57 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Restatement of comparatives (Tables)
12 Months Ended
Jun. 30, 2023
Text block [abstract]  
Schedule Of Material Restatement Of EVT 801 Asset The error resulted in a material overstatement of the
EVT-801
intangible asset and a corresponding overstatement of the liability at acquisition. The impact of this error is noted below with the restated balances disclosed in note 15 and 19.
 
    
30 June 2021
Reported
   
Increase/
(decrease)
   
1 July 2021
Restated
   
30 June 2022
Reported
   
Increase/
(decrease)
   
30 June 2022
Restated
 
    
A$’000
   
A$’000
   
A$’000
   
A$’000
   
A$’000
   
A$’000
 
             
Consolidated statement of financial position
                                                
             
Intangibles - licensing agreement
     27,265       (1,044     26,221       27,266       (1,045     26,221  
Less Accumulated amortisation
     (5,263     50       (5,213     (7,216     134       (7,082
       22,002       (994     21,008       20,050       (911     19,139  
Current contingent consideration
     (3,164     2,373       (791     (759     —         (759
Non-Current
contingent consideration
     (8,926     (1,377     (10,303     (8,756     547       (8,209
       (12,091     997       (11,094     (9,515     547       (8,968
Net Assets
     37,851       2       37,853       18,638       (364     18,274  
Accumulated losses
     (44,205     2       (44,203     (68,253     (364     (68,617
Total equity
     37,851       2       37,853       18,638       (364     18,274  
Schedule Of Material Restatement Of Income Statement
 
 
  
30 June 2022
 
 
Increase/
(decrease)
 
 
30 June 2022
Restated
 
 
30 June 2021
 
 
Increase/
(decrease)
 
  
30 June 2021
Restated
 
Consolidated statement of profit and loss
  
 
 
 
 
  
Research and development expense (Amortisation)
     (20,252      83        (20,169
 
 
(14,541
 
     
  
 
(14,541
General and administrative expense (foreign exchange impact)
     (4,511      (450      (4,961
 
 
(7,022
 
 
2
 
  
 
(7,020
Loss on revaluation of contingent consideration
     (152      —          (152
 
 
(2,570
 
     
  
 
(2,570
Commercialisation expense
     (127      —          (127
 
     
 
     
  
     
Loss before tax
     (25,016      (366      (25,382
 
 
(8,906
 
 
2
 
  
 
(8,904
Income tax benefit
     368        —          368  
 
 
484
 
 
     
  
 
484
 
Loss after tax
     (24,648      (366      (25,014
 
 
(8,422
 
   
2
 
  
 
(8,420
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share                           
 
     
 
     
  
     
Basic loss for the year attributable to equity holders
     (18.61      (0.27      (18.88
 
 
(7.16
 
     
  
 
(7.16
Diluted loss for the year attributable to equity holders
     (18.61      (0.27      (18.88
 
 
(7.16
 
     
  
 
(7.16